quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:12·466d
SECFiling
Poseida Therapeutics Inc. logo

SEC Form EFFECT filed by Poseida Therapeutics Inc.

PSTX· Poseida Therapeutics Inc.
Health Care
Original source

Companies

  • PSTX
    Poseida Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Dec 2UpdatePiper Sandler$10.00
  • Jan 4UpdateH.C. Wainwright$15.00
  • Jan 7UpdateCantor Fitzgerald$24.00

Related

  • PR274d
    Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
  • PR371d
    Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
  • SEC457d
    SEC Form 15-12G filed by Poseida Therapeutics Inc.
  • SEC465d
    Amendment: SEC Form SCHEDULE 13D/A filed by Poseida Therapeutics Inc.
  • SEC466d
    SEC Form EFFECT filed by Poseida Therapeutics Inc.
  • INSIDER468d
    Large owner Malin Life Sciences Holdings Ltd closing all direct ownership in the company (SEC Form 4)
  • SEC470d
    SEC Form S-8 POS filed by Poseida Therapeutics Inc.
  • SEC470d
    SEC Form S-8 POS filed by Poseida Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022